Division of Pulmonary and Critical Care Medicine, NorthShore University HealthSystem, Evanston, IL, USA.
Sleep Med. 2011 Jun;12(6):538-41. doi: 10.1016/j.sleep.2010.09.017. Epub 2011 May 14.
Servo ventilation (SV) devices generate positive airway pressure with a variable pressure support that changes in response to a patient's own respiratory output. Two currently available SV devices-VPAP-AdaptSV® and BIPAP-AutoSV®-have been used in treatment of complex sleep apnea (CompSAS), but no side-by-side comparisons are available.
Data of 76 consecutive patients with complex sleep apnea, who were prescribed a VPAP-AdaptSV® or BIPAP-AutoSV® in a non-randomized parallel design, were retrospectively analyzed. Patients underwent a diagnostic polysomnogram followed by a continuous positive airway pressure (CPAP) titration and a SV titration study. Objective compliance with the device was assessed at the first visit at 4-6weeks of its use.
Thirty-five patients received a VPAP-AdaptSV® device, while 41 patients were treated with BIPAP-AutoSV®. Patients treated with BIPAP-AutoSV® had a significantly higher apnea-hypopnea index during their CPAP titration study than patients treated with VPAP-AdaptSV® [49/h (28-60) vs. 35/h (19.5-49.5), median (interquartile range), p<0.001]. On follow-up, 56 patients (73.7%) were using their device. Mean nightly use was 5.0h (2.8-6.4) for VPAP-AdaptSV® group and 6.0h (3.5-7.2) for BIPAP-AutoSV® group (p=0.081); an improvement in Epworth Sleepiness Scale score was higher in the BIPAP-AutoSV® group than in the VPAP-AdaptSV® group [4 (1-9) vs. 2.5 (0-5), p=0.02].
Our retrospective data indicate that the two servo-ventilation devices are comparable means of controlling complex sleep apnea, and the compliance with them is high.
伺服通气(SV)设备通过可变压力支持产生正气道压力,该压力支持根据患者自身的呼吸输出而变化。目前有两种可用的 SV 设备-VPAP-AdaptSV®和 BIPAP-AutoSV®-已用于治疗复杂睡眠呼吸暂停(CompSAS),但尚无并列比较。
回顾性分析了以非随机平行设计接受 VPAP-AdaptSV®或 BIPAP-AutoSV®治疗的 76 例连续复杂睡眠呼吸暂停患者的数据。患者接受诊断性多导睡眠图检查,然后进行持续气道正压通气(CPAP)滴定和 SV 滴定研究。在使用设备后的 4-6 周内,首次就诊时评估设备的客观依从性。
35 例患者接受 VPAP-AdaptSV®设备治疗,41 例患者接受 BIPAP-AutoSV®治疗。CPAP 滴定研究中,接受 BIPAP-AutoSV®治疗的患者呼吸暂停低通气指数明显高于接受 VPAP-AdaptSV®治疗的患者[49/h(28-60)比 35/h(19.5-49.5),中位数(四分位距),p<0.001]。随访时,56 例患者(73.7%)正在使用他们的设备。VPAP-AdaptSV®组平均每晚使用 5.0h(2.8-6.4),BIPAP-AutoSV®组 6.0h(3.5-7.2)(p=0.081);BIPAP-AutoSV®组的 Epworth 嗜睡量表评分改善高于 VPAP-AdaptSV®组[4(1-9)比 2.5(0-5),p=0.02]。
我们的回顾性数据表明,这两种伺服通气设备是控制复杂睡眠呼吸暂停的两种等效手段,并且它们的依从性很高。